Myocarditis associated with doxorubicin cardiotoxicity
- PMID: 8356947
- DOI: 10.1093/ajcp/100.2.158
Myocarditis associated with doxorubicin cardiotoxicity
Abstract
In contrast to previous reports, the authors were impressed by the frequency of myocarditis in the endomyocardial biopsy specimens of patients treated with anthracyclines. To examine this, they reviewed the histologic and electron microscopic results and immunoperoxidase stains of myocardial biopsy specimens from 11 patients with doxorubicin cardiotoxicity grades 1.0-3.0. Immunoperoxidase stains for lymphocytes, macrophages, and endothelial cells and induced expression of Class II antigen were performed using the avidin-biotin complex procedure. A full panel of monoclonal antibodies was employed on fresh-frozen tissue; a smaller panel was used with formaldehyde-fixed paraffin-embedded material. Four of the 11 endomyocardial biopsy specimens showed myocarditis, and 2 showed borderline myocarditis by the Dallas criteria. The infiltrating lymphocytes were generally characterized as T lymphocytes and were associated with induced Class II antigen expression by arterial endothelial cells. In addition, foci of replacement fibrosis, suggesting a chronic process, were identified. Although this association does not prove a causal relationship, these results suggest that myocarditis can be a component of doxorubicin-induced myocardial injury.
Similar articles
-
Ten-year experience with endomyocardial biopsy in myocarditis presenting with congestive heart failure: frequency, pathologic characteristics, treatment and follow-up.G Ital Cardiol. 1997 Mar;27(3):209-23. G Ital Cardiol. 1997. PMID: 9199949 Clinical Trial.
-
Utility of immunofluorescence and electron microscopy in endomyocardial biopsies from patients with unexplained heart failure.Cardiovasc Pathol. 2010 Jul-Aug;19(4):e99-105. doi: 10.1016/j.carpath.2009.04.004. Epub 2009 Jun 6. Cardiovasc Pathol. 2010. PMID: 19502086
-
Assessment of the inflammatory process by endomyocardial biopsy in patients with dilated cardiomyopathy based on pathological and immunohistochemical methods.Kardiol Pol. 2006 May;64(5):479-87; discussion 488. Kardiol Pol. 2006. PMID: 16752331 English, Polish.
-
Endomyocardial biopsy.Cardiovasc Clin. 1985;15(1):141-63. Cardiovasc Clin. 1985. PMID: 3916087 Review.
-
Improving the therapeutic index of anthracycline chemotherapy: focus on liposomal doxorubicin (Myocet).Breast. 2009 Aug;18(4):218-24. doi: 10.1016/j.breast.2009.05.004. Epub 2009 Aug 4. Breast. 2009. PMID: 19656681 Review.
Cited by
-
Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation.Int J Nanomedicine. 2007;2(4):567-83. Int J Nanomedicine. 2007. PMID: 18203425 Free PMC article. Review.
-
p21(WAF1/Cip1/Sdi1) knockout mice respond to doxorubicin with reduced cardiotoxicity.Toxicol Appl Pharmacol. 2011 Nov 15;257(1):102-10. doi: 10.1016/j.taap.2011.08.024. Epub 2011 Sep 3. Toxicol Appl Pharmacol. 2011. PMID: 21920376 Free PMC article.
-
Myocarditis occurrence with cancer immunotherapy across indications in clinical trial and post-marketing data.Sci Rep. 2021 Aug 30;11(1):17324. doi: 10.1038/s41598-021-96467-5. Sci Rep. 2021. PMID: 34462476 Free PMC article.
-
Endothelial-to-Mesenchymal Transition: Potential Target of Doxorubicin-Induced Cardiotoxicity.Am J Cardiovasc Drugs. 2023 May;23(3):231-246. doi: 10.1007/s40256-023-00573-w. Epub 2023 Feb 26. Am J Cardiovasc Drugs. 2023. PMID: 36841924 Review.
-
Mitochondrial Determinants of Doxorubicin-Induced Cardiomyopathy.Circ Res. 2020 Mar 27;126(7):926-941. doi: 10.1161/CIRCRESAHA.119.314681. Epub 2020 Mar 26. Circ Res. 2020. PMID: 32213135 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical